Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The Open Source Registry for Rare Diseases (OSSE) provides a concept and a software for the management of registries for patients with rare diseases. A disease is defined as rare if less than 5 out of 10,000 people are affected. Up to date, approximately 6,000 rare diseases are catalogued. Networking and data exchange for research purposes remains challenging due to the paucity of interoperability and due to the fact that small data stocks are stored locally. The so called "Findable, Accessible, Interoperable, Reusable" (FAIR) Data Principles have been developed to improve research in the field of rare diseases. Subsequently, the OSSE architecture was adapted to implement the FAIR Data Principles. Therefore, the so-called FAIR Data Point was integrated into OSSE to provide a description of metadata in a FAIR manner. OSSE relies on the existing metadata repository (MDR), which is used in to define data elements in the system. This is an important step towards unified documentation across multiple registries. The integration and use of new procedures to improve interoperability plays an important role in the context of registries for rare diseases.

Download full-text PDF

Source

Publication Analysis

Top Keywords

rare diseases
24
fair data
16
data principles
12
registry rare
8
data
7
rare
7
diseases
6
osse
5
fair
5
osse fair
4

Similar Publications

Objective: Systematize the methodological decisions adopted in the budget impact analyses of the recommendation reports of the National Commission for the Incorporation of Technologies into the Unified Health System (Conitec) regarding drugs incorporated into the SUS (Brazilian Unified Health System) in the period from 2012 to 2024.

Methods: This is an exploratory, descriptive, retrospective study, based on document analysis of Conitec's technical recommendation reports with decisions on the incorporation of drugs published up to 2024. Information from the Budget Impact Analyses (BIA) was extracted and presented in terms of percentage, median and interquartile range.

View Article and Find Full Text PDF

In silico biophysics and rheology of blood and red blood cells in Gaucher Disease.

PLoS Comput Biol

September 2025

Division of Applied Mathematics, Brown University, Providence, Rhode Island, United States of America.

Gaucher Disease (GD) is a rare genetic disorder characterized by a deficiency in the enzyme glucocerebrosidase, leading to the accumulation of glucosylceramide in various cells, including red blood cells (RBCs). This accumulation results in altered biomechanical properties and rheological behavior of RBCs, which may play an important role in blood rheology and the development of bone infarcts, avascular necrosis (AVN) and other bone diseases associated with GD. In this study, dissipative particle dynamics (DPD) simulations are employed to investigate the biomechanics and rheology of blood and RBCs in GD under various flow conditions.

View Article and Find Full Text PDF

Human myelinated brain organoids with integrated microglia as a model for myelin repair and remyelinating therapies.

Sci Transl Med

September 2025

Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Oligodendrocytes, the myelinating cells of the central nervous system (CNS), are essential for the formation of myelin sheaths and pivotal for maintaining axonal integrity and conduction. Disruption of these cells and the myelin sheaths they produce is a hallmark of demyelinating conditions like multiple sclerosis or those resulting from certain drug side effects, leading to profound neurological impairments. In this study, we created a human brain organoid comprising neurons, astrocytes, and myelinating oligodendrocytes.

View Article and Find Full Text PDF

Primary coenzyme Q (CoQ) deficiency is a mitochondrial disorder with variable clinical presentation and limited response to standard CoQ10 supplementation. Recent studies suggest that 4-hydroxybenzoic acid (4-HBA), a biosynthetic precursor of CoQ, may serve as a substrate enhancement treatment in cases caused by pathogenic variants in COQ2, a gene encoding a key enzyme in CoQ biosynthesis. However, it remains unclear whether 4-HBA is required throughout life to maintain health, whether it offers advantages over CoQ10 treatment, and whether these findings are translatable to humans.

View Article and Find Full Text PDF

BACKGROUND Non-traumatic bladder rupture, a rare yet potentially life-threatening condition, can stem from diverse factors such as malignancies, bladder inflammation, or bladder diverticulum rupture. Pelvic radiotherapy, in extremely rare instances, can lead to radiation cystitis and subsequent bladder fistula formation. Patients with such conditions often present with abdominal pain, hematuria, oliguria, and urinary ascites.

View Article and Find Full Text PDF